

A L E R T

November 22, 2021

TO: Outpatient Service Providers, Physicians, Nurse Practitioners, Physician Assistants, Federally Qualified Health Centers and Rural Health Clinics**RE: COVID-19 Monoclonal Antibody Infusion**

As Alabama Medicaid continues to monitor the COVID-19 national emergency in Alabama, Medicaid is adding the following procedure codes for coverage:

CPT CODE	SUMMARY	Effective date
Q0240	Injection, casirivimab and imdevimab, 600 mg.	7/30/2021
M0240	Intravenous infusion, or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses.	7/30/2021
M0241	Intravenous infusion, or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses.	7/30/2021
Q0243	Injection, casirivimab and imdevimab, 2400 mg.	11/21/2020
Q0244	Injection, casirivimab.	6/3/2021
M0243	Intravenous infusion, or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring.	11/21/2020
M0244	Intravenous infusion, or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency.	5/6/2021
Q0245	Injection, bamianivimab and etesevimab, 2100 mb.	2/9/2021
M0245	Intravenous infusion, bamianivimab and etesevimab, includes infusion and post administration monitoring.	2/9/2021
M0246	Intravenous infusion, bamianivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency.	5/6/2021
Q0247	Injection, sotrovimab, 500 mg.	5/26/2021
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring.	5/26/2021

A L E R T

M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency.	5/26/2021
-------	--	-----------

Providers may submit claims for dates of service on or after the effective dates for each procedure code as listed above.

FQHCs/RHCs should submit claims for the above procedure codes outside of the encounter rate.

Providers may find the reimbursement rates for the COVID-19 testing procedure codes on Medicaid's website at www.Medicaid.Alabama.gov by selecting Fee Schedules under the Providers tab.

As a reminder, providers must deliver services within their scope of practice and have the proper certification and licensure to perform these tests.

During the COVID-19 emergency, it is important to file claims as quickly as possible to ensure payment from Medicaid to Medicaid providers close to the date of service. The Centers for Medicare and Medicaid Services (CMS) has increased the federal matching percentage for the emergency time frame, but states can only receive the increased match on claims paid during the emergency. Providers should include appropriate COVID-19 diagnosis code(s) on claims submitted to help with tracking of COVID-19.

For questions, please visit the Medicaid website at www.Medicaid.Alabama.gov, or call the Medicaid Fiscal Agent at 1-800-688-7989.

Physicians, Nurse Practitioners, and Physician Assistants can email questions to Jean.Wackerle@medicaid.alabama.gov.

Laboratory service providers can email questions to Susan.Watkins@medicaid.alabama.gov.

Outpatient service providers can email questions to Lynne.Davenport@medicaid.alabama.gov or Callie.Johnson@medicaid.alabama.gov.